| Trade Date |
Insider |
Title |
Buy or Sell |
Quantity |
Security Type |
Price |
Proceeds |
Transaction Conviction |
Position Quantity |
Position Value |
Positon Conviction |
SEC Link |
Nature of Ownership |
2020-06-16 | Robert Lorne Hopfner | - | Buy | 93,000 | Common Stock | $16.00 | -$1,488,000.00 | - | 2,222,967 | $35,567,472.00 | - | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2020-06-16 | Robert Lorne Hopfner | - | Buy | 211,237 | Common Stock | $0.00 | $0.00 | - | 2,129,967 | $0.00 | - | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2020-06-16 | Robert Lorne Hopfner | - | Buy | 226,236 | Common Stock | $0.00 | $0.00 | - | 1,918,730 | $0.00 | - | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2020-06-16 | Robert Lorne Hopfner | - | Buy | 1,692,494 | Common Stock | $0.00 | $0.00 | - | 1,692,494 | $0.00 | - | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2020-06-16 | Patrick J Heron | - | Buy | 250,000 | Common Stock | $16.00 | -$4,000,000.00 | 51.67 [ Very High ] | 2,309,554 | $36,952,864.00 | 477.32 [Very High] | Form 4 | By Frazier Life Sciences VIII, L.P. | 2020-06-16 | Patrick J Heron | - | Buy | 140,824 | Common Stock | $0.00 | $0.00 | - | 2,059,554 | $0.00 | 425.65 [Very High] | Form 4 | By Frazier Life Sciences VIII, L.P. | 2020-06-16 | Patrick J Heron | - | Buy | 226,236 | Common Stock | $0.00 | $0.00 | - | 1,918,730 | $0.00 | 396.55 [Very High] | Form 4 | By Frazier Life Sciences VIII, L.P. | 2020-06-16 | Patrick J Heron | - | Buy | 1,692,494 | Common Stock | $0.00 | $0.00 | - | 1,692,494 | $0.00 | 349.79 [Very High] | Form 4 | By Frazier Life Sciences VIII, L.P. | 2020-06-16 | Tpg Group Holdings (sbs) Advisors, Inc. | - | Buy | 4,219,053 | Common Stock | $0.00 | $0.00 | - | 4,219,053 | $0.00 | - | Form 4 | See Explanation of Responses | 2020-06-16 | Tpg Group Holdings (sbs) Advisors, Inc. | - | Buy | 937,500 | Common Stock | $16.00 | -$15,000,000.00 | - | 5,156,553 | $82,504,848.00 | - | Form 4 | See Explanation of Responses | 2020-06-16 | Kurt Von Emster | - | Buy | 2,185,415 | Common Stock, $0.001 par value per share | $0.00 | $0.00 | - | 2,185,415 | $0.00 | - | Form 4 | See Footnotes | 2020-06-16 | Kurt Von Emster | - | Buy | 1,217,074 | Common Stock, $0.001 par value per share | $0.00 | $0.00 | - | 3,402,489 | $0.00 | - | Form 4 | See Footnotes | 2020-06-16 | Kurt Von Emster | - | Buy | 454,812 | Common Stock, $0.001 par value per share | $0.00 | $0.00 | - | 3,857,301 | $0.00 | - | Form 4 | See Footnotes | 2020-06-16 | Kurt Von Emster | - | Buy | 298,917 | Common Stock, $0.001 par value per share | $0.00 | $0.00 | - | 4,156,218 | $0.00 | - | Form 4 | See Footnotes | 2020-06-16 | Kurt Von Emster | - | Buy | 12,500 | Common Stock, $0.001 par value per share | $16.00 | -$200,000.00 | - | 4,168,718 | $66,699,488.00 | - | Form 4 | See Footnotes | 2020-09-29 | Ra Capital Management, L.p. | - | Sell | 80,707 | Common Stock | $52.08 | $4,203,220.56 | 15.85 [ Very High ] | 5,408,474 | $281,673,325.92 | 1,062.07 [Very High] | Form 4 | See Footnote | 2020-09-30 | Ra Capital Management, L.p. | - | Sell | 124,656 | Common Stock | $50.27 | $6,266,457.12 | 24.48 [ Very High ] | 5,283,818 | $265,617,530.86 | 1,037.59 [Very High] | Form 4 | See Footnote | 2020-10-07 | Ra Capital Management, L.p. | - | Sell | 98,597 | Common Stock | $50.95 | $5,023,517.15 | 19.36 [ Very High ] | 5,169,254 | $263,373,491.30 | 1,015.09 [Very High] | Form 4 | See Footnote | 2020-10-08 | Ra Capital Management, L.p. | - | Sell | 167,661 | Common Stock | $50.69 | $8,498,736.09 | 32.92 [ Very High ] | 5,001,593 | $253,530,749.17 | 982.17 [Very High] | Form 4 | See Footnote | 2020-12-09 | William J Newell | - | Buy | 22,228 | Common Stock | $1.29 | -$28,674.12 | 4.36 [ Very High ] | 66,684 | $86,022.36 | 13.09 [Average] | Form 4 | - | 2020-12-15 | Tpg Group Holdings (sbs) Advisors, Inc. | - | Sell | 6,276 | Common Stock | $33.02 | $207,233.52 | 1.23 [ High ] | 5,150,277 | $170,062,146.54 | 1,010.85 [Very High] | Form 4 | See Explanation of Responses | 2020-12-15 | Tpg Group Holdings (sbs) Advisors, Inc. | - | Sell | 75,703 | Common Stock | $32.46 | $2,457,319.38 | 14.86 [ Very High ] | 5,074,574 | $164,720,672.04 | 995.99 [Very High] | Form 4 | See Explanation of Responses | 2020-12-21 | Grant Pickering | President & CEO | Buy | 15,000 | Common Stock | $1.79 | -$26,850.00 | 2.94 [ Very High ] | 588,191 | $1,052,861.89 | 115.44 [Very High] | Form 4 | - | 2020-12-21 | Grant Pickering | President & CEO | Sell | 7,196 | Common Stock | $28.42 | $204,510.32 | 1.41 [ High ] | 580,995 | $16,511,877.90 | 114.03 [Very High] | Form 4 | - | 2020-12-21 | Grant Pickering | President & CEO | Sell | 5,691 | Common Stock | $29.08 | $165,494.28 | 1.12 [ High ] | 575,304 | $16,729,840.32 | 112.92 [Very High] | Form 4 | - | 2020-12-21 | Grant Pickering | President & CEO | Sell | 2,113 | Common Stock | $29.88 | $63,136.44 | 0.41 [ Average ] | 573,191 | $17,126,947.08 | 112.50 [Very High] | Form 4 | - | 2020-12-28 | Grant Pickering | President & CEO | Buy | 5,500 | Common Stock | $1.79 | -$9,845.00 | 1.08 [ High ] | 578,691 | $1,035,856.89 | 113.58 [Very High] | Form 4 | - | 2020-12-29 | Jeff Fairman | VP, Research | Buy | 740 | Common Stock | $1.79 | -$1,324.60 | 0.15 [ Low ] | 1,408 | $2,520.32 | 0.28 [Very Low] | Form 4 | - | 2021-01-06 | Robert Lorne Hopfner | - | Sell | 34,913 | Common Stock | $29.24 | $1,020,856.12 | 6.85 [ Very High ] | 2,188,054 | $63,978,698.96 | 429.45 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-06 | Robert Lorne Hopfner | - | Sell | 22,507 | Common Stock | $29.99 | $674,984.93 | 4.42 [ Very High ] | 2,165,547 | $64,944,754.53 | 425.03 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-07 | Robert Lorne Hopfner | - | Sell | 24,524 | Common Stock | $27.75 | $680,541.00 | 4.81 [ Very High ] | 2,141,023 | $59,413,388.25 | 420.22 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-07 | Robert Lorne Hopfner | - | Sell | 22,587 | Common Stock | $28.80 | $650,505.60 | 4.43 [ Very High ] | 2,118,436 | $61,010,956.80 | 415.79 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-07 | Robert Lorne Hopfner | - | Sell | 469 | Common Stock | $29.51 | $13,840.19 | 0.09 [ Very Low ] | 2,117,967 | $62,501,206.17 | 415.70 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-08 | Robert Lorne Hopfner | - | Sell | 31,468 | Common Stock | $26.43 | $831,699.24 | 6.18 [ Very High ] | 2,086,499 | $55,146,168.57 | 409.52 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-08 | Robert Lorne Hopfner | - | Sell | 8,944 | Common Stock | $27.08 | $242,203.52 | 1.76 [ High ] | 2,077,555 | $56,260,189.40 | 407.76 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-08 | Robert Lorne Hopfner | - | Sell | 200 | Common Stock | $28.23 | $5,646.00 | 0.04 [ Very Low ] | 2,077,355 | $58,643,731.65 | 407.72 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-11 | Paul Sauer | SVP Process Dev, Manufacturing | Buy | 2,500 | Common Stock | $1.79 | -$4,475.00 | 0.49 [ Average ] | 80,399 | $143,914.21 | 15.78 [Average] | Form 4 | - | 2021-01-11 | Paul Sauer | SVP Process Dev, Manufacturing | Sell | 973 | Common Stock | $25.38 | $24,694.74 | 0.19 [ Low ] | 79,426 | $2,015,831.88 | 15.59 [Average] | Form 4 | - | 2021-01-11 | Paul Sauer | SVP Process Dev, Manufacturing | Sell | 1,527 | Common Stock | $26.74 | $40,831.98 | 0.30 [ Average ] | 77,899 | $2,083,019.26 | 15.29 [Average] | Form 4 | - | 2021-01-11 | Robert Lorne Hopfner | - | Sell | 12,480 | Common Stock | $25.42 | $317,241.60 | 2.45 [ High ] | 2,064,875 | $52,489,122.50 | 405.27 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-11 | Robert Lorne Hopfner | - | Sell | 24,980 | Common Stock | $26.69 | $666,716.20 | 4.90 [ Very High ] | 2,039,895 | $54,444,797.55 | 400.37 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-11 | Robert Lorne Hopfner | - | Sell | 12,206 | Common Stock | $27.02 | $329,806.12 | 2.40 [ High ] | 2,027,689 | $54,788,156.78 | 397.98 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-12 | Robert Lorne Hopfner | - | Sell | 17,666 | Common Stock | $26.35 | $465,499.10 | 3.47 [ Very High ] | 2,010,023 | $52,964,106.05 | 394.51 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-12 | Robert Lorne Hopfner | - | Sell | 901 | Common Stock | $27.05 | $24,372.05 | 0.18 [ Low ] | 2,009,122 | $54,346,750.10 | 394.33 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-13 | Robert Lorne Hopfner | - | Sell | 26,010 | Common Stock | $25.90 | $673,659.00 | 5.11 [ Very High ] | 1,983,112 | $51,362,600.80 | 389.23 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-13 | Robert Lorne Hopfner | - | Sell | 3,100 | Common Stock | $26.34 | $81,654.00 | 0.61 [ Average ] | 1,980,012 | $52,153,516.08 | 388.62 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-14 | Robert Lorne Hopfner | - | Sell | 14,918 | Common Stock | $25.88 | $386,077.84 | 2.93 [ Very High ] | 1,965,094 | $50,856,632.72 | 385.69 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-15 | Robert Lorne Hopfner | - | Sell | 22,869 | Common Stock | $25.74 | $588,648.06 | 4.49 [ Very High ] | 1,942,225 | $49,992,871.50 | 381.20 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-15 | Robert Lorne Hopfner | - | Sell | 3,808 | Common Stock | $26.05 | $99,198.40 | 0.75 [ Average ] | 1,938,417 | $50,495,762.85 | 380.45 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-19 | Robert Lorne Hopfner | - | Sell | 42,516 | Common Stock | $25.55 | $1,086,283.80 | 8.34 [ Very High ] | 1,895,901 | $48,440,270.55 | 372.11 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-19 | Robert Lorne Hopfner | - | Sell | 7,000 | Common Stock | $26.05 | $182,350.00 | 1.37 [ High ] | 1,888,901 | $49,205,871.05 | 370.74 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-15 | Jane Wright-mitchell | General Counsel | Buy | 2,500 | Common Stock | $2.03 | -$5,075.00 | 0.49 [ Average ] | 4,062 | $8,245.86 | 0.80 [Very Low] | Form 4 | - | 2021-01-15 | Jane Wright-mitchell | General Counsel | Sell | 2,500 | Common Stock | $26.00 | $65,000.00 | 0.49 [ Average ] | 1,562 | $40,612.00 | 0.31 [Very Low] | Form 4 | - |
